AMZB Patent Approval for Treating HIV Infection

[LadyTrader]

Tuesday, September 05 2006 6:00 PM, EST

--------------------------------------------------------------------------------

Amazon Biotech, Inc. Announces Patent Approval for a Unique Formulation and Method of Treating HIV Infection

NEW YORK, NY -- (MARKET WIRE) -- 09/05/06 -- Amazon Biotech, Inc. (OTCBB: AMZB) (FRANKFURT: B2D.F) today announced that it has a Notice of Allowance from the UnitedStates Patent and Trademark Office, advising that Amazon's application forpatent protection of its investigative drug named AMZ0026 has beenapproved.

AMZ0026, a therapeutic herbal composition, is Amazon Biotech's primary drugcandidate and is currently approved by the FDA to undergo Phase I/IIstudies in humans. AMZ0026 has been shown to exhibit potentialtherapeutically beneficial effects on the immune system of immunodeficientHIV/AIDS patients, particularly with respect to elevation of CD4 levels inpreliminary clinical case studies.

Dr. Mechael Kanovsky, President of Amazon Biotech, stated, "We are verypleased to receive the notice of allowance. We believe that this eventsignificantly strengthens our intellectual property rights and increasesour potential value."

About Amazon Biotech, Inc.

Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarilydeveloping immune modulator drugs. AMZ0026 is the company's first suchdrug, which is to be used for the treatment of HIV/AIDS. The company planson initiating Phase I/II clinical studies of AMZ0026 in the near future,with an eventual goal of attracting a joint venture partner with a majorpharmaceutical company in Phase III trials, or follow the FDA Fast Trackprogram to market. Amazon Biotech specializes in natural plantpharmaceutical drugs and is focused on bringing healthier pharmaceuticaldrugs to market.

Additional information on Amazon Biotech may be found at:http://www.amazonbiotech.com.

Forward-Looking Statements

"Safe-Harbor" Statement Under the Private Securities Litigation Reform Actof 1995 This press release contains forward-looking information within themeaning of Section 21E of the Securities Exchange Act of 1934, includingstatements regarding any potential sales of products as well as statementsthat include the words "believes," "expects," "anticipates," or similarexpressions. Such forward-looking statements involve known and unknownrisks, uncertainties and other factors that may cause the actual results,performance or achievements of Amazon Biotech, to differ materially fromthose implied or expressed by such forward-looking statements. Such factorsinclude, among others, the risk factors included in Amazon Biotech'ssubsequent reports filed with the Securities and Exchange Commission underthe Exchange Act. This press release speaks as of the date first set forthabove and Amazon Biotech assumes no responsibility to update theinformation included herein for events occurring after the date hereof.

Contact:LC GroupRick Lutz(404) 261-1196

http://biz.yahoo.com/iw/060905/0159946.html

[LadyTrader]

float 18.5 mil
OS 37.6 mil

[bohogirl]

Looks really good LT.
Low float, pretty much on the bottom, huge news - could move really nicely in the next couple of days as the news starts spreading.

[LadyTrader]

common microcap..get ur shyt together ...everyone else has it..sheesh

http://biz.yahoo.com/iw/060905/0159946.html

http://news.moneycentral.msn.com/ticker/article.asp?Feed=MW&Date=20060905&ID=5995524&Symbol=US:AMZB

http://studio.financialcontent.com/Engine?Account=macreport&PageName=NEWSREAD&ID=3599742&Ticker=AMZB&SOURCE=06159946.nitf

http://www.marketwire.com/mw/release_html_b1?release_id=159946

[LadyTrader]

Tuesday, September 05 2006 6:00 PM, EST

--------------------------------------------------------------------------------

Amazon Biotech, Inc. Announces Patent Approval for a Unique Formulation and Method of Treating HIV Infection

NEW YORK, NY -- (MARKET WIRE) -- 09/05/06 -- Amazon Biotech, Inc. (OTCBB: AMZB) (FRANKFURT: B2D.F) today announced that it has a Notice of Allowance from the UnitedStates Patent and Trademark Office, advising that Amazon's application forpatent protection of its investigative drug named AMZ0026 has beenapproved.

AMZ0026, a therapeutic herbal composition, is Amazon Biotech's primary drugcandidate and is currently approved by the FDA to undergo Phase I/IIstudies in humans. AMZ0026 has been shown to exhibit potentialtherapeutically beneficial effects on the immune system of immunodeficientHIV/AIDS patients, particularly with respect to elevation of CD4 levels inpreliminary clinical case studies.

Dr. Mechael Kanovsky, President of Amazon Biotech, stated, "We are verypleased to receive the notice of allowance. We believe that this eventsignificantly strengthens our intellectual property rights and increasesour potential value."

About Amazon Biotech, Inc.

Amazon Biotech, Inc. is a natural plant pharmaceutical company, primarilydeveloping immune modulator drugs. AMZ0026 is the company's first suchdrug, which is to be used for the treatment of HIV/AIDS. The company planson initiating Phase I/II clinical studies of AMZ0026 in the near future,with an eventual goal of attracting a joint venture partner with a majorpharmaceutical company in Phase III trials, or follow the FDA Fast Trackprogram to market. Amazon Biotech specializes in natural plantpharmaceutical drugs and is focused on bringing healthier pharmaceuticaldrugs to market.

Additional information on Amazon Biotech may be found at:http://www.amazonbiotech.com.

Forward-Looking Statements

"Safe-Harbor" Statement Under the Private Securities Litigation Reform Actof 1995 This press release contains forward-looking information within themeaning of Section 21E of the Securities Exchange Act of 1934, includingstatements regarding any potential sales of products as well as statementsthat include the words "believes," "expects," "anticipates," or similarexpressions. Such forward-looking statements involve known and unknownrisks, uncertainties and other factors that may cause the actual results,performance or achievements of Amazon Biotech, to differ materially fromthose implied or expressed by such forward-looking statements. Such factorsinclude, among others, the risk factors included in Amazon Biotech'ssubsequent reports filed with the Securities and Exchange Commission underthe Exchange Act. This press release speaks as of the date first set forthabove and Amazon Biotech assumes no responsibility to update theinformation included herein for events occurring after the date hereof.

Contact:LC GroupRick Lutz(404) 261-1196


http://mct1.microcaptrade.com/newsservlet?transID=N5EF8C8B7-BE8A-40C4-BE5C-3FEDAE518480200609051800MRKTWIREUSPR____0159946

[LadyTrader]

lunch time dip there to fill the morning gap...bid support building ..4 x 2 now .lookin good for after lunch run....

[LadyTrader]

holding up nicely.....if we can hold eod here tomorrow should be fun...

[LadyTrader]

great close today !!...Huge buys EOD........tomorow is gona be even better...nice chart we painted today ......:mrgreen:

[LadyTrader]

MACD just broke thru and on its way up today.......:mrgreen:

http://i4.photobucket.com/albums/y133/VonBon/amzb3.png

[LadyTrader]

L2's looking good and its real early yet......145 / .16......i expect it up a lil higher by open........:mrgreen:

[LadyTrader]

Thursday, September 07 2006 9:17 AM, EST

--------------------------------------------------------------------------------

AMZB, EGIL, GGTS, HALO, MDLH Have Also Been Added To Naked Short List Today

Location: the United States

Date: 2006-09-07

Provider Name: M2

Service Name: Press Wire

M2 PressWIRE - September 7, 2006 - www.buyins.net, announced today that these select companies have been added to the NASDAQ, AMEX and NYSE naked short threshold list: Amazon Biotech, Inc. (OTCBB: AMZB), Edgetech International, Inc. (OTC: EGIL), Gaming Transactions Inc. (OTC: GGTS), Halo Technology Holdings, Inc. (OTCBB: HALO), Medical International Technology, Inc. (OTCBB: MDLH). For a complete list of companies on the naked short list please visit our web site. To find the SqueezeTrigger Price before a short squeeze starts in any stock, go to www.buyins.net.

Amazon Biotech, Inc. (OTCBB: AMZB) a development stage company, engages in the research and development of all-natural drugs in the United States. The company owns the rights to a HIV/AIDS drug, AMZ 0026, a naturally derived pharmaceutical product, consisting of 11 natural plant substances that enable metabolic processes to support immune system function. In addition, it owns the rights to a natural hair growth product, AMZ HG001, which contains proprietary herbal ingredients. The company is based in New York City. With 37.59 million shares outstanding and 30,698 shares declared short as of August 2006, there is a failure to deliver in shares of AMZB.



About BUYINS.NET

WWW.BUYINS.NET is a service designed to help bonafide shareholders of publicly traded US companies fight naked short selling. Naked short selling is the illegal act of short selling a stock when no affirmative determination has been made to locate shares of the stock to hypothecate in connection with the short sale. Buyins.net has built a proprietary database that uses Threshold list feeds from NASDAQ, AMEX and NYSE to generate detailed and useful information to combat the naked short selling problem. For the first time, actual trade by trade data is available to the public that shows the attempted size, actual size, price and average value of short sales in stocks that have been shorted and naked shorted. This information is valuable in determining the precise point at which short sellers go out-of-the-money and start losing on their short and naked short trades.

BUYINS.NET has built a massive database that collects, analyzes and publishes a proprietary SqueezeTrigger for each stock that has been shorted, www.buyins.net/squeezetrigger.pdf. The SqueezeTrigger database of nearly 950,000,000 short sale transactions goes back to January 1, 2005, and calculates the exact price at which the Total Short Interest is short in each stock. This data was never before available prior to January 1, 2005, because the Self Regulatory Organizations (primary exchanges) guarded it aggressively. After the SEC passed Regulation SHO, exchanges were forced to allow data processors like Buyins.net to access the data.

The SqueezeTrigger database collects individual short trade data on over 7,000 NYSE, AMEX and NASDAQ stocks and general short trade data on nearly 8,000 OTCBB and PINKSHEET stocks. Each month the database grows by approximately 50,000,000 short sale transactions and provides investors with the knowledge necessary to time when to buy and sell stocks with outstanding short positions. By tracking the size and price of each month's short transactions, BUYINS.NET provides institutions, traders, analysts, journalists and individual investors the exact price point where short sellers start losing money.


BUYINS.NET affiliates, officers, directors and employees may also have bought or may buy the shares discussed in this opinion and may profit in the event those shares rise in value. GGTS has previously paid a $995.00 data fee to BUYINS.NET. Market commentary provided by Thomas Ronk.


This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission.

http://mct1.microcaptrade.com/newsservlet?transID=NB7D3274F-791B-44AD-A9A2-238657CF7210200609070859M2______EUPR_____17_0

[clay]

Anyone still have any comments on this one?